Dr. Maida has been responsible for negotiating partnering and licensing transactions with many premier pharmaceutical companies and academic centers of excellence, including, among others, Eli Lilly, Novartis, RCT Corporation, Astra Zeneca, Pfizer, Bristol Myers Squibb, MD Anderson, Yale University, Stanford University, University of California San Francisco and Davis, and the Wistar Institute. Dr. Maida's already strong scientific expertise was further strengthened as he recently completed and in 2010 received a PhD in Tumor Immunology. On the financial front, Dr. Maida has served for years as a key adviser to many large institutional investors for their oncology investments. Dr. Maida serves on several boards in the oncology field, including Spectrum Pharmaceuticals and others. Earlier in his career, Dr. Maida served for a number of years as the Chief Financial Officer of a large public company's subsidiary and Senior Financial Controller of a $1.7 billion division of that company (Lockheed).
Ms. Powers has served as Chairman of NWBT for the last 4 years, and brings more than 25 years' experience in corporate transactions and operations, including more than a decade specializing in building biotech companies through Toucan Capital. Ms. Powers is particularly well known for her experience in building biotech companies that are developing cell therapies, including both immune cell therapies (such as NWBT's DCVax®) and adult stem cell therapies. Such products -- consisting of living human cells -- require fundamentally different manufacturing, storage, distribution and handling than do pharmaceutical drugs ("pills in bottles"). Such living cell products also involve different clinical and regulatory requirements, and different business and cost/pricing models, than traditional drugs. The cell therapy companies which Ms. Powers has been involved in building over the last decade,
|SOURCE Northwest Biotherapeutics|
Copyright©2010 PR Newswire.
All rights reserved